Four years after its last inquiry into competition in the pharmaceutical market, the French competition authority is to look into how the prices of medicines are set, the level of rebates in the generics market, and the “economic and competitive balance of the pharmaceutical distribution chain.”
The French competition authority is launching a fresh sector inquiry into competition in the pharmaceutical market, this time with a view to reining in the prices of reimbursable medicines as well as boosting competition in the pharmaceutical distribution chain.
The inquiry will also look at what it describes as “apparently inflated” prices of generics, and whether the...
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
A total of 748 key medicines are now affected by the four-month stock requirement, compared with 422 in 2021.
The UK will require all antibiotic manufacturers looking to apply for funding under its subscription payment model to demonstrate they are meeting waste discharge standards in a bid to reduce antimicrobial resistance.
Joint clinical assessment reports must be descriptive rather than reach definitive conclusions, and must not interfere with national decision making processes, according to new EU guidance.
Developments in India and Pakistan are designed to standardize how drug companies disclose their expenses associated with health care professionals.
The agency’s plan for advanced manufacturing seeks more harmonization, while also seeking to codify internal practices with guidance and training.
